التفاصيل البيبلوغرافية
| العنوان: |
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy |
| المؤلفون: |
Danilo Rocco, Alex Friedlaender, Alfredo Addeo, Marina Chiara Garassino, Diego Signorelli, Alessandro Russo, Vincenzo Sforza, Alessio Cortellini, Katia Cannita, Daniele Santini, Pietro Di Marino, Federica Zoratto, Marco Russano, Paolo Marchetti, Francesca Rastelli, Rossana Berardi, Rita Chiari, Alain Gelibter, Giampiero Porzio, Paolo Bironzo, Giuseppe L Banna, Joachim GJV Aerts, Fausto Barbieri, Diego L Cortinovis, Francesco Passiglia, Mariangela Torniai, Carlo Genova, Alessandro Inno, Giovanni Mansueto, Fabrizio Citarella, Luca Cantini, Miriam G Ferrara, Lorenza Landi, Luigi Della Gravara, Serena Ricciardi, Alessandro De Toma, Vincenzo Adamo, Alessandro Leonetti, Ettore D'Argento, Erika Rijavec, Annalisa Guida, Marco Siringo, Marianna Macerelli, De Tursi Michele, Antonino Grassadonia, Alessandro Tuzi, Paola Bordi, Gabriele Minuti, Giulio Metro, Gian Paolo Spinelli |
| المصدر: |
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021) |
| بيانات النشر: |
BMJ Publishing Group, 2021. |
| سنة النشر: |
2021 |
| المجموعة: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: |
Background Some concomitant medications including antibiotics (ATB) have been reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in unselected patients with non-small cell lung cancer (NSCLC) (according to programmed death-ligand 1 (PD-L1) expression and treatment line). Whether such relationship is causative or associative is matter of debate.Methods We present the outcomes analysis according to concomitant baseline medications (prior to ICI initiation) with putative immune-modulatory effects in a large cohort of patients with metastatic NSCLC with a PD-L1 expression ≥50%, receiving first-line pembrolizumab monotherapy. We also evaluated a control cohort of patients with metastatic NSCLC treated with first-line chemotherapy. The interaction between key medications and therapeutic modality (pembrolizumab vs chemotherapy) was validated in pooled multivariable analyses.Results 950 and 595 patients were included in the pembrolizumab and chemotherapy cohorts, respectively. Corticosteroid and proton pump inhibitor (PPI) therapy but not ATB therapy was associated with poorer performance status at baseline in both the cohorts. No association with clinical outcomes was found according to baseline statin, aspirin, β-blocker and metformin within the pembrolizumab cohort. On the multivariable analysis, ATB emerged as a strong predictor of worse overall survival (OS) (HR=1.42 (95% CI 1.13 to 1.79); p=0.0024), and progression free survival (PFS) (HR=1.29 (95% CI 1.04 to 1.59); p=0.0192) in the pembrolizumab but not in the chemotherapy cohort. Corticosteroids were associated with shorter PFS (HR=1.69 (95% CI 1.42 to 2.03); p |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
2051-1426 |
| Relation: |
https://jitc.bmj.com/content/9/4/e002421.full; https://doaj.org/toc/2051-1426 |
| DOI: |
10.1136/jitc-2021-002421 |
| URL الوصول: |
https://doaj.org/article/8143f97c38ab481c9154bd8703e472e1 |
| رقم الانضمام: |
edsdoj.8143f97c38ab481c9154bd8703e472e1 |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder